Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD
Combined therapy with finerenone and SGLT2i is associated with less MAKE and all-cause mortality in CKD patients compared with monotherapy. However, the risk of hyperkalemia with finerenone warrants caution.
Authors
- Ming‐Yan Jiang (ORCID: https://orcid.org/0000-0002-9817-3131)
- Yun‐Ting Huang (ORCID: https://orcid.org/0000-0001-5273-8654)
- Vin‐Cent Wu (ORCID: https://orcid.org/0000-0001-7935-0991)
- Wei‐Chih Kan (ORCID: https://orcid.org/0000-0003-2401-6536)
- Chih-Chiang Chien (ORCID: https://orcid.org/0000-0001-7761-763X)
- Jui‐Yi Chen (ORCID: https://orcid.org/0000-0003-1376-7780)
- Min‐Hsiang Chuang (ORCID: https://orcid.org/0000-0002-8538-4861)
- Hsien-Yi Wang
Institutions
- Chung Hwa University of Medical Technology (TW)
- National Taiwan University Hospital (TW)
- Chi Mei Medical Center (TW)
- Chia Nan University of Pharmacy and Science (TW)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1093/ndt/gfaf064
- Citations
- 9
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 13.67
Funders
- Chi Mei Medical Center